Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

November 27, 2022

View Archives Issues

  • Renal Cancer

    A 61-year-old man presented to the emergency room with back pain of approximately one month duration. His medical history was significant for hypertension, for which he received diltiazem 180 mg daily. His weight had been stable at 175 lbs and, other than back pain, he suffered no constitutional symptoms. He has worked as an auto mechanic for 40 years. He smokes approximately 20 cigarettes a day and has done so for all of his adult years. He has no family history of cancer.
  • Breast Cancer in Men

    Breast cancer occurs in approximately 1 in 100,000 men each year, a rate that is slightly less than 1% of that in women.
  • Erlotinib Maintenance for Patients with Advanced NSCLC

    In a multinational trial of erlotinib (Tarceva®) for patients with advanced NSCLC following conventional chemotherapy, improved progression-free and overall survival were demonstrated. The improvement was approximately one week for PFS and one month for OS. However, for the subset with demonstrable activating mutations in the EGFR gene, the benefit of erlotinib treatment was more substantial.
  • PET Scan Predicts Survival After Transplant for Relapsed Diffuse Large B-Cell Lymphoma

    High-dose chemotherapy and autologous hematopoietic stem cell transplant (ASCT) is standard therapy for relapsed or refractory diffuse large B-cell lymphoma after salvage chemotherapy. In this retrospective study of 39 patients with diffuse large B-cell lymphoma (DLCL) who had undergone ASCT, the authors assessed outcomes based on post-salvage pre-ASCT PET imaging. PET scans were positive in 17 (44%) and negative in 22 (56%) after salvage. A negative PET scan predicted for less relapse and better three-year OS at 81%, compared to 39% for PET-positive patients. Results are excellent for patients achieving PET negativity prior to ASCT; the optimal approach for PET-positive patients remains undefined.
  • Clinical Briefs in Primary Care Supplement

  • Pharmacology Watch

    WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.